Harp P, Tanaka D, Pope C N
Division of Toxicology, College of Pharmacy and Health Sciences, Northeast Louisiana University, Monroe 71209, USA.
Fundam Appl Toxicol. 1997 May;37(1):64-70. doi: 10.1006/faat.1997.2301.
Phenylmethylsulfonyl fluoride (PMSF), a nonneuropathic inhibitor of neurotoxic esterase (NTE), is a known potentiator of organophosphorus-induced delayed neurotoxicity (OPIDN). The ability of PMSF posttreatment (90 mg/kg, sc, 4 hr after the last PSP injection) to modify development of delayed neurotoxicity was examined in 2-, 5-, and 8-week-old White Leghorn chickens treated either one, two, or three times (doses separated by 24 hr) with the neuropathic OP compound phenyl saligenin phosphate (PSP, 5 mg/kg, sc). NTE activity was measured in the cervical spinal cord 4 hr after the last PSP treatment. Development of delayed neurotoxicity was measured over a 16-day postexposure period. All PSP-treated groups exhibited > 97% NTE inhibition regardless of age or number of OP treatments. Two-week-old birds did not develop clinical signs of neurotoxicity in response to either single or repeated OP treatment regimens nor following subsequent treatment with PMSF. Five-week-old birds were resistant to the clinical effects of a single PSP exposure and were minimally affected by repeated doses. PMSF posttreatment, however, significantly amplified the clinical effects of one, two, or three doses of PSP. A single exposure to PSP induced slight to moderate signs of delayed neurotoxicity in 8-week-old birds with more extensive neurotoxicity being noted following repeated dosing. As with 5-week-old birds, PMSF exacerbated the clinical signs of neurotoxicity when given after one, two, or three doses of PSP in 8-week-old birds. Axonal degeneration studies supported the clinical findings: PMSF posttreatment did not influence the degree of degeneration in 2-week-old chickens but resulted in more severe degeneration (relative to PSP only exposure) in cervical cords from both 5- and 8-week-old birds. The results indicate that PMSF does not alter the progression of delayed neurotoxicity in very young (2 weeks of age) chickens but potentiates PSP-induced delayed neurotoxicity in the presence of 0-3% residual NTE activity in older animals. We conclude that posttreatment with neuropathic or nonneuropathic NTE inhibitors, following virtually complete NTE inhibition by either single or repeated doses of a neuropathic agent in sensitive age groups, can modify both the clinical and morphological indices of delayed neurotoxicity. This study further supports the hypothesis that potentiation of OPIDN occurs through a mechanism unrelated to NTE.
苯甲基磺酰氟(PMSF)是神经毒性酯酶(NTE)的一种非神经性抑制剂,是已知的有机磷诱导的迟发性神经毒性(OPIDN)的增强剂。在2周龄、5周龄和8周龄的白来航鸡中,研究了PMSF治疗后(90mg/kg,皮下注射,在最后一次PSP注射后4小时)对迟发性神经毒性发展的影响,这些鸡用神经性OP化合物苯基水杨苷磷酸酯(PSP,5mg/kg,皮下注射)处理一次、两次或三次(剂量间隔24小时)。在最后一次PSP处理后4小时,测量颈脊髓中的NTE活性。在暴露后的16天内测量迟发性神经毒性的发展。所有PSP处理组无论年龄或OP处理次数如何,均表现出>97%的NTE抑制。2周龄的鸡对单次或重复的OP处理方案均未出现神经毒性的临床症状,在随后用PMSF处理后也未出现。5周龄的鸡对单次PSP暴露的临床影响具有抗性,并且受重复剂量的影响最小。然而,PMSF治疗后显著增强了一剂、两剂或三剂PSP的临床效果。单次暴露于PSP会在8周龄的鸡中诱发轻度至中度的迟发性神经毒性症状,重复给药后会出现更广泛的神经毒性。与5周龄的鸡一样,在8周龄的鸡中,在一剂、两剂或三剂PSP后给予PMSF会加剧神经毒性的临床症状。轴突变性研究支持了临床发现:PMSF治疗后并不影响2周龄鸡的变性程度,但导致5周龄和8周龄鸡颈脊髓中更严重的变性(相对于仅暴露于PSP)。结果表明,PMSF不会改变非常年幼(2周龄)鸡迟发性神经毒性的进展,但在老年动物中存在0 - 3%的残余NTE活性时会增强PSP诱导的迟发性神经毒性。我们得出结论,在敏感年龄组中,用神经性或非神经性NTE抑制剂进行治疗后,在单次或重复剂量的神经性药物几乎完全抑制NTE后,可以改变迟发性神经毒性的临床和形态学指标。这项研究进一步支持了OPIDN增强是通过与NTE无关的机制发生的这一假设。